Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BR1010 in Essential Hypertension Patients Uncontrolled on Fimasartan/Amlodipine
NCT03991442Phase 3Completed
- Sponsor
- Boryung
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fimasartan, amlodipine and hydrochlorothiazide in essential hypertension (2 arms), sponsored by Boryung. Primary endpoint: sitting systolic blood pressure at 8 weeks. Started Jun 2019; status: completed.
02
Drugs
fimasartanamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03991442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991442.